Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts

The Lancet Respiratory Medicine

Volumn 3, Issue 6, 2015, Pages 416-417

  Brusselle, Guy G ^a,b   Bracke, Ken ^a   Lahousse, Lies ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; EOSINOPHIL COUNT; HUMAN; NOTE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; BLOOD; DRUG EFFECTS; EOSINOPHIL; FEMALE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; EOSINOPHILS; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84930872686     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00145-9     Document Type: Note

References (13)

1. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
2. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184:662-671.
3. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
4. Ernst P, Saad N, Suissa S Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015, 45:525-537.
5. Suissa S Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013, 68:540-543.
6. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015, published online April 13. http://dx.doi.org/10.1016/S2213-2600(15)00106-X.
7. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013, 1:210-223.
8. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012, 185:612-619.
9. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013, 13:11.
10. Eltboli O, Mistry V, Barker B, Brightling CE Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology 2015, published online Jan 27. 10.1111/resp.12475.
11. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-971.
12. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005, 60:193-198.
13. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013, 1:e29-e30. Respiratory Effectiveness Group.